New study tracks Dupilumab's Real-Life impact on kids with severe eczema

NCT ID NCT06415175

Ongoing Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extra treatments or tests are given beyond standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab
What this could lead to: If successful, this could provide real-world evidence on how well dupilumab works for severe eczema in young children, helping guide treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It only includes children in Spain, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Investigational Site Number : 7240001

Madrid, 28007, Spain
Investigational Site Number : 7240002

Alicante, 03010, Spain
Investigational Site Number : 7240003

Barcelona, 08041, Spain
Investigational Site Number : 7240004

Santiago de Compostela, A Coruña [La Coruña], 15706, Spain
Investigational Site Number : 7240005

Oviedo, Principality of Asturias, 33011, Spain
Investigational Site Number : 7240006

Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain
Investigational Site Number : 7240007

Madrid, 28031, Spain
Investigational Site Number : 7240008

Seville, Sevilla, 41013, Spain
Investigational Site Number : 7240009

San Cristóbal de La Laguna, 38320, Spain
Investigational Site Number : 7240010

Madrid, 28009, Spain
Investigational Site Number : 7240011

Zaragoza, 50009, Spain
Investigational Site Number : 7240012

Palma, 07120, Spain
Investigational Site Number : 7240013

Málaga, 29010, Spain
Investigational Site Number : 7240014

Madrid, 28046, Spain
Investigational Site Number : 7240016

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.